Cytek BioSciences (CTKB) stock is soaring 6.48% in pre-market trading on Thursday, following the release of its better-than-expected third-quarter earnings report. The advanced medical equipment and technology company reported a narrower loss than analysts had forecast, boosting investor confidence.

For the quarter ended September 30, Cytek BioSciences posted an adjusted loss of 4 cents per share, surpassing the mean expectation of a 5-cent loss from five analysts. This performance also marked an improvement from the 7-cent loss reported in the previous quarter. Revenue for the period rose 1.5% year-over-year to $52.29 million, exceeding analyst expectations of $51.49 million.

Despite the positive quarterly results, Cytek BioSciences still faces challenges. The company reported a quarterly net loss of $5.48 million, and its shares have lost 39.8% year-to-date. However, Wall Street remains optimistic about the stock's potential. The current average analyst rating is "buy," with a median 12-month price target of $4.25, representing a 5.6% upside from its last closing price. As Cytek BioSciences continues to navigate the competitive advanced medical equipment sector, investors will be watching closely to see if the company can maintain its momentum and return to profitability.